During a Community Case Forum event, Stacey Stein, MD, discussed data guiding the use of current regimens for the treatment ...

China’s response to new United States (U.S.) tariffs could complicate the supply of important medicines, an analysis of data ...

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

We are delighted to welcome Dr. Nicacio to the Protara team,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “As a proven leader with deep expertise spanning all stages of ...

Popular Western medicines for diseases including cancer and diabetes have been caught in the escalating U.S.-China trade war, ...

Amgen's global Phase III DeLLphi-304 trial of Imdelltra has met its primary endpoint at a planned interim analysis for ...

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy ...

The FDA granted approval for the use of Skytrofa (lonapegsomatropin) in September 2021 for the treatment of pediatric ...

David Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard ...

With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an unmet need in personalized cancer treatment, offering n ...

Patients with solid tumor malignancies had better survival after ICI therapy if they were obese than if they had a normal BMI.